Dopamine D2 antagonists

While the obvious value of in vivo animal models is clear, there also are instances—especially in cases of inflammatory arthritis, behavior, and tumor growth—where they have failed to be predictive of useful clinical activity in humans [51], For example, leukotriene (LTB4) antagonists showed activity in animal models of inflammatory arthritis yet failed to be useful in rheumatoid arthritis [52]. Similarly, dopamine D4 antagonists showed activity in animal behavior models previously predictive of dopamine D2 antagonists in schizophrenia. However, testing of dopamine D4 antagonists showed no efficacy in humans [53]. 

Norinder, U., Hogberg, T., A quantitative structure-activity relationship for some dopamine D2 antagonists of benzamide type, Acta Pharm. Nord. 1992, 4, 73-78. 

Dopamine D2 antagonists, Tachykinin NK3 antagonists, Neurokinin NK3 antagonists, etc. 

Mihara K, Kondo T, Suzuki A, et al. No relationship between -141 C Ins/Del polymorphism in the promoter region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonists in schizophrenic patients a preliminary study. Psychiatry Res 2001 101(l) 33 8. 

Dopamine D2 antagonist 17.7 Modeller MOBILE Gold 1000 diverse MDDR 50 20 4(1) — [32]... 

---